Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
The approach involves in-depth molecular simulations of the target protein by itself and in complex with its primary partner proteins, paired with ensemble virtual screening that factors in conformational mobility in both the unbound and complex states. The tentative binding pockets are identified at the protein-protein interaction interface and in distant allosteric areas, aiming to capture the full range of mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O00548
UPID:
DLL1_HUMAN
Alternative names:
Drosophila Delta homolog 1
Alternative UPACC:
O00548; B2RAK7; B5M0B3; Q9NU41; Q9UJV2
Background:
Delta-like protein 1, also known as Drosophila Delta homolog 1, plays a pivotal role in cell differentiation, development, and immune system function. It acts as a ligand for NOTCH receptors, facilitating cell communication that regulates cell lineage and morphogenesis. Its involvement in brain development, stem cell maintenance, and immune system development underscores its significance in human physiology.
Therapeutic significance:
Given its role in neurodevelopmental disorders with non-specific brain abnormalities, Delta-like protein 1 presents a promising target for therapeutic intervention. Understanding the role of Delta-like protein 1 could open doors to potential therapeutic strategies.